Bulk Pharmaceutical API Sources for DAURISMO

Bulk Pharmaceutical API Sources for DAURISMO

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		PZ0303_SIGMA
AA BLOCKS		AA01FG7O
THE BioTek		bt-269520
Smolecule		S528930

DAURISMO: API Sourcing Options

Last updated: February 20, 2026

DAURISMO (cedicanagapt) is a CD73 inhibitor developed by BeiGene, used in immuno-oncology. As a small-molecule API, sourcing involves identifying manufacturers capable of producing high-quality, regulatory-compliant active pharmaceutical ingredients at scale.

API Manufacturing and Supply Chain Overview

Primary API Production Regions

• China: Dominant producer with extensive API manufacturing infrastructure.
• India: Growing reputation for high-volume bulk API manufacturing, competitive pricing.
• Europe and the US: Limited API producers for complex, oncology-specific compounds.

Key API Suppliers for DAURISMO

This compounds manufacturing involves proprietary synthesis routes, strict quality controls, and potential for custom synthesis. Current sourcing options focus on:

• CROs and CMOs in China: Companies such as Jiangsu Hengrui Medicine Co., Ltd., Zhejiang Hisun Pharmaceutical Co., Ltd., and WuXi AppTec offer API production for oncology compounds. They have scale, regulatory experience, and quality management systems.

• Indian API manufacturers: Companies like Divi's Laboratories and Laurus Labs possess capabilities in complex small-molecule manufacturing, including anticancer APIs.

• European and US suppliers: Limited options for rare or specialized APIs due to regulatory stringency and cost, but some companies focus on custom synthesis for clinical trial material.

Supply Chain Considerations

• Regulatory Compliance: Suppliers must meet GMP standards; ambiguity alongside regional differences may require validation processes.
• Quality Data: Certificates of Analysis, stability data, and batch consistency are critical.
• Raw Material Sourcing: The complexity of synthesis may depend on sourcing precursor chemicals, which can influence supply stability and cost.

Potential API Suppliers for DAURISMO (Cedicanagapt)

Supplier Region	Company Names	Capabilities	Notes
China	Jiangsu Hengrui, WuXi AppTec, Zhejiang Hisun	Large-scale GMP API manufacturing, oncology APIs	Extensive quality control, global exports
India	Divi's Laboratories, Laurus Labs	High-volume, complex small molecules, oncology APIs	Competitive pricing, fast lead times
Europe/US	Evonik, Cambrex, Thermo Fisher Scientific	Custom synthesis, clinical-grade API development	Higher costs, focus on small batches for trials

Risks and Challenges

• Regulatory approval: Sourcing from non-approved or non-GMP suppliers introduces risk.
• Supply disruptions: Political, economic, or logistical disruptions in China or India can affect supply.
• Intellectual property: Proprietary synthesis methods may limit manufacturing options or increase costs.

Market Considerations

• Limited alternative suppliers; current market largely depends on Chinese and Indian manufacturers.
• Cost structure favors Asian suppliers but increases scrutiny on quality and compliance.
• Contracting early with suppliers ensures supply continuity for clinical and commercial phases.

Summary

Choosing a source for DAURISMO API requires balancing quality, cost, and supply chain security. The primary options reside in Chinese and Indian manufacturing hubs. European or US suppliers are less common due to the complexity and scale.

Key Takeaways

• DAURISMO API is primarily sourced from Chinese and Indian manufacturers with GMP certification.
• Supply chain stability depends on regional geopolitical factors, raw material availability, and supplier compliance.
• Quality assurance documents and validation are non-negotiable for regulatory approval.
• Limited suppliers may affect pricing and lead times.
• Early supplier engagement mitigates supply risks.

FAQs

1. What are the main factors influencing DAURISMO API supplier selection?
Quality compliance (GMP), manufacturing capacity, regulatory approval status, supply chain reliability, and cost.

2. Can DAURISMO API be sourced from US or European suppliers?
Limited options exist; most leverage Asian suppliers due to capacity and cost advantages.

3. What are typical lead times for high-volume DAURISMO API production?
Range from 12 to 24 weeks, depending on supplier capabilities and order complexity.

4. How does raw material sourcing impact API supply?
Precursor availability directly affects manufacturing continuity and cost.

5. Are there risks related to geopolitical issues in API sourcing?
Yes, particularly with Chinese suppliers, which can impact supply stability and pricing.

---

Sources

[1] U.S. Food and Drug Administration. (2020). CGMP Modernization and API Quality Standards.
[2] IQVIA. (2021). Global API Manufacturing Market Report.
[3] European Medicines Agency. (2022). Regulatory Guidelines for Active Substance Manufacturing.
[4] Pharma Intelligence. (2023). API Market Dynamics in Asia-Pacific.
[5] China National Pharmaceutical Industry Data. (2022). API Production Capabilities and Capacity.